Ozempic Lawsuits 2026: Gastroparesis and Vision Loss Updates

If you or someone you know has taken Ozempic for weight loss or diabetes, you may have heard about the growing number of lawsuits. As of January 2026, over 3,000 individual lawsuits have been consolidated into two main federal court proceedings. These cases focus on two severe side effects: gastroparesis (stomach paralysis) and vision loss, including blindness from a condition called NAION.

The first Ozempic lawsuit was filed in August 2023, and since then, the litigation has expanded rapidly. No global settlements have been reached yet, but the legal process is moving forward with thousands of plaintiffs seeking answers and compensation.

This article breaks down the latest legal updates, examines the medical evidence linking Ozempic to these injuries, and explains what steps you can take if you've been affected.

Key Takeaways

1. Thousands of lawsuits are pending against Novo Nordisk, alleging Ozempic can cause severe gastroparesis and permanent vision loss (NAION).
2. Strong medical studies show a significantly increased risk of NAION (4x to 7x higher) and gastroparesis for semaglutide users.
3. Two separate federal court proceedings (MDLs) are now handling these claims, with a dedicated MDL for vision loss created in late 2025.
4. The FDA has issued some warnings but has not yet required a specific NAION warning on the U.S. label, despite international regulatory action.
5. If you've been injured, you may qualify to file a lawsuit. Consult with an attorney who specializes in pharmaceutical mass torts to understand your options.

What Are the Latest Legal Updates on the Ozempic Lawsuits?

The Ozempic litigation is one of the most watched mass tort cases in the country. To handle the volume, the federal court system has created two separate Multidistrict Litigations (MDLs), which group similar cases together for efficiency.

• The Gastroparesis MDL: This group, known as MDL 3094, includes claims of severe gastrointestinal injuries like gastroparesis, ileus (impaired bowel function), and intestinal obstruction. As of early 2026, this MDL contains the majority of the over 3,000 pending cases.
• The Vision Loss MDL: In a significant move in December 2025, a federal judicial panel established a second, separate MDL specifically for lawsuits alleging vision loss and blindness. This decision recognized that claims involving optic nerve damage involve different medical evidence than stomach injury cases.

Both MDLs are being overseen by the same judge in the Eastern District of Pennsylvania, U.S. District Judge Karen Marston. The creation of the vision loss MDL is a major development, indicating the courts are taking these claims seriously. As of late 2025, there were about 30 federal and over 40 state court cases focused on vision loss, with more expected to join the new MDL.

Is There a Proven Link Between Ozempic and Vision Loss or Blindness?

A key allegation in the new vision loss lawsuits is that Ozempic can cause Non‑Arteritic Anterior Ischemic Optic Neuropathy (NAION). NAION is a sudden, painless loss of vision in one eye caused by reduced blood flow to the optic nerve. It can result in permanent partial or total blindness.

Recent scientific studies have found a strong statistical association between semaglutide (the active ingredient in Ozempic) and NAION:

• A 2024 study published in JAMA Ophthalmology analyzed data from over 16,800 patients. It found that people with type 2 diabetes prescribed semaglutide had a 4.28 times higher risk of developing NAION compared to those on other diabetes medications. For overweight or obese patients taking semaglutide for weight loss, the risk was 7.64 times higher.
• Another large 2024 study involving over 400,000 patients in the Netherlands found that people with type 2 diabetes who used semaglutide had more than double the risk of developing NAION.

While these observational studies show a strong link, they cannot prove direct causation. However, the findings have prompted regulatory attention. In June 2025, the World Health Organization (WHO) warned that semaglutide drugs may "rarely" cause NAION and advised patients to seek immediate medical care for sudden vision changes. Similarly, the European Medicines Agency has ordered updated warning labels to include NAION risk.

How Strong is the Medical Evidence in the Ozempic Litigation?

The strength of the medical evidence varies between the gastroparesis and vision loss claims, which is a central point in the legal disputes.

For Vision Loss (NAION): The evidence is considered stronger from a litigation standpoint. The sudden and severe nature of NAION, coupled with the recent high‑profile studies showing a significant increased risk, creates a clearer narrative for juries. Plaintiffs argue that this risk was not disclosed, depriving them of the chance to make an informed decision about using the drug.

For Gastroparesis: The evidence is also substantial but more complex. A 2025 retrospective cohort study published in BMJ Open Gastroenterology found that individuals with obesity (without diabetes) treated with semaglutide had a 3.33 times higher risk of developing gastroparesis compared to those treated with bupropion‑naltrexone, and a 6.14 times higher risk compared to those who had sleeve gastrectomy surgery.

However, the defense argues that gastroparesis is a known complication of diabetes itself, making it harder to prove the drug directly caused the condition in some patients. This is a key battleground in the gastroparesis MDL.

What Warnings Has the FDA Issued About Ozempic Side Effects?

The U.S. Food and Drug Administration (FDA) has taken several actions regarding Ozempic's side effects, but plaintiffs argue the warnings are still insufficient.

• Gastrointestinal Warnings: The FDA added a warning for ileus (intestinal blockage) to the Ozempic label in September 2023. In January 2025, the label was updated to state that Ozempic is "not recommended in patients with severe gastroparesis. Critics note this does not warn that the drug can cause the condition.
• Vision Warnings: As of early 2026, the FDA has not required a specific warning for NAION on Ozempic's U.S. label. The current label mentions "vision changes" as a potential side effect and highlights concerns about diabetic retinopathy, but does not name NAION. There is growing pressure from ophthalmologists and patient advocates for the FDA to mandate a stronger "black box" warning for vision loss.
• Promotional Oversight: In September 2025, the FDA issued a warning letter to Novo Nordisk concerning a promotional video, stating it created a "misleading impression regarding the safety" of Ozempic and other drugs. This shows increased regulatory scrutiny of the drug's marketing.

Who Qualifies to File an Ozempic Lawsuit, and What Does a Lawyer Do?

You may qualify to file an Ozempic lawsuit if you were prescribed Ozempic, Wegovy, Rybelsus, or a similar GLP‑1 drug and were subsequently diagnosed with either:

• Gastroparesis (stomach paralysis), confirmed by a gastric emptying study.
• Non‑Arteritic Anterior Ischemic Optic Neuropathy (NAION) or other sudden, permanent vision loss.

What a Lawyer Does: An experienced mass tort attorney will evaluate your case for free. If you have a claim, they will:

1. Gather all your medical records linking your injury to the drug.
2. File your individual lawsuit, which will then become part of the appropriate MDL.
3. Handle all communication with the court and the drug manufacturer's legal team.
4. Work with other plaintiffs' lawyers to build a strong collective case through discovery and expert testimony.
5. Negotiate for a settlement on your behalf if one is reached, or prepare your case for trial.

It's important to know that an MDL is not a class action. You retain your own lawyer and your own claim for damages based on your specific injuries and losses. While no settlements have been reached yet, some legal analysts project potential settlement ranges from $50,000 to over $700,000 per case, depending on the severity of the injury and the strength of the evidence.

As a Patient, How Should I Weigh the Benefits of Weight Loss Against the Lawsuit Risks?

This is a deeply personal decision that should be made in close consultation with your doctor. Here’s a balanced way to think about it:

• Acknowledge the Benefits: Ozempic and similar GLP‑1 drugs are highly effective for managing type 2 diabetes and promoting significant weight loss, which can dramatically improve overall health and reduce the risk of heart disease, stroke, and other obesity‑related conditions.
• Understand the Real Risks: While severe side effects like gastroparesis and NAION are considered rare, the lawsuits highlight that they can be life‑altering. Being informed means knowing the full spectrum of possible outcomes.
• Have an Informed Conversation: Ask your doctor:
  • "Given my personal health history, am I at a higher risk for these severe gastrointestinal or vision side effects?"
  • "Are there alternative medications with a different risk profile we should consider?"
  • "What are the specific warning signs of gastroparesis or NAION that I should watch for?"
• Monitor Your Health: If you choose to take Ozempic, be vigilant. Seek immediate medical attention for symptoms like persistent, severe vomiting, abdominal pain, bloating, or a sudden change in your vision.